Clinical Trial Update: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating fingolimod (Gilenya) in patients with neutralizing antibodies against interferon has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 4 | Status: WITHDRAWN